- Home
- PUMP vs JANX Comparison
PUMP vs JANX Comparison
Compare PUMP & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PUMP | JANX |
|---|---|---|
| Founded | 2007 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 840.4M |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PUMP | JANX |
|---|---|---|
| Price | $14.90 | $14.21 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 13 |
| Target Price | $14.14 | ★ $47.00 |
| AVG Volume (30 Days) | ★ 5.3M | 865.7K |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 100.76 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,269,158,000.00 | $10,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $15.61 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.51 | $12.12 |
| 52 Week High | $18.50 | $35.34 |
Technical Indicators
Market Signals| Indicator | PUMP | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 43.24 | 52.31 |
| Support Level | $13.88 | $13.88 |
| Resistance Level | $15.34 | $14.64 |
| Average True Range (ATR) | 0.82 | 0.53 |
| MACD | -0.11 | 0.03 |
| Stochastic Oscillator | 26.33 | 63.43 |
Price Performance
Historical ComparisonAbout PUMP ProPetro Holding Corp.
ProPetro Holding Corp is a Texas-based oilfield services company. It provides hydraulic fracturing, wireline, and other complementary services to oil and gas companies engaged in the exploration and production of North American oil and natural gas resources. The company focused on the Permian Basin. The operating segments of the company are hydraulic fracturing which generates key revenue, wireline, cementing, and power generation service.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.